` Comparison: 059210 vs ALGN - Alpha Spread

M
059210
vs
ALGN

Over the past 12 months, Metabiomed Co Ltd has outperformed ALGN, delivering a return of +25% compared to the ALGN's +8% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
059210
ALGN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

M
Intrinsic Value
13 127.69 KRW
Undervaluation 61%
Intrinsic Value
Price
ALGN Intrinsic Value
185.2 USD
Overvaluation 2%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
M
Metabiomed Co Ltd
KOSDAQ:059210
5 090 KRW
Align Technology Inc
NASDAQ:ALGN
189.3 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
059210, ALGN

059210
ALGN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
M
Metabiomed Co Ltd
Revenue
Align Technology Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
059210, ALGN

059210
ALGN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
M
Metabiomed Co Ltd
KOSDAQ:059210
Align Technology Inc
NASDAQ:ALGN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Metabiomed Co Ltd
23%
ALGN
67.2%

Operating Margin

Metabiomed Co Ltd
11.9%
ALGN
14.5%

Net Margin

Metabiomed Co Ltd
12.9%
ALGN
10.2%

FCF Margin

Metabiomed Co Ltd
-1.7%
ALGN
14%

ROE

Metabiomed Co Ltd
20.3%
ALGN
10.5%

ROA

Metabiomed Co Ltd
5.7%
ALGN
6.6%

ROIC

Metabiomed Co Ltd
5.4%
ALGN
7.5%

ROCE

Metabiomed Co Ltd
11.8%
ALGN
13.9%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
059210, ALGN

Loading
059210
ALGN
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
059210, ALGN

Loading
059210
ALGN
Difference
www.alphaspread.com

Performance By Year
059210, ALGN

Loading
059210
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 059210 to other stocks
MDLN
Medline Inc
M
More expensive
vs Metabiomed Co Ltd
7741
Hoya Corp
More expensive
vs Metabiomed Co Ltd
ALC
Alcon AG
More expensive
vs Metabiomed Co Ltd
COLO B
Coloplast A/S
More expensive
vs Metabiomed Co Ltd
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett